Nitazoxanide Antiparasitic Drug Induces Ferroptosis in TNBC (Redox Reports 2026)
A 2026 preclinical study shows nitazoxanide, an FDA-approved antiparasitic drug, triggers ferroptosis in TNBC cells by disrupting iron homeostasis and degrading the beta-catenin/GPX4 axis. The findings are based on in vitro and zebrafish xenograft data only.
By Sanare Lab · August 8, 2026 · 4 min read
Key Takeaway
Nitazoxanide (NTZ), an FDA-approved antiparasitic drug, triggers ferroptosis — a form of iron-dependent programmed cell death — in triple-negative breast cancer (TNBC) cells by disrupting iron homeostasis and degrading β-catenin, which suppresses glutathione peroxidase 4 (GPX4). In a 2026 preclinical study, NTZ inhibited proliferation, migration, and invasion of TNBC cells in vitro and reduced tumor growth in a zebrafish xenograft model at clinically relevant doses. These findings are preclinical only; no human clinical trials have evaluated NTZ for TNBC.
Triple-negative breast cancer (TNBC) remains one of the most challenging subtypes to treat, lacking targeted therapies beyond conventional chemotherapy. Ferroptosis — a form of iron-dependent programmed cell death — has emerged as a promising therapeutic strategy for TNBC, but existing ferroptosis inducers remain suboptimal in clinical practice.
In a 2026 study published in Redox Reports, researchers investigated whether nitazoxanide (NTZ), an FDA-approved antiparasitic drug with known anticancer and redox activity, could be repurposed as a ferroptosis inducer for TNBC. The results provide the first preclinical evidence supporting this mechanism.
Table of Contents
- Study Design and Methods
- Key Findings: Ferroptosis Induction
- Mechanistic Insights
- Clinical Implications and Limitations
- Frequently Asked Questions
Study Design and Methods
The study used two TNBC cell lines — MDA-MB-231 and Hs578T — to evaluate the anticancer effects of nitazoxanide. Researchers assessed cell viability, clonogenicity (the ability of cells to form colonies), migration, and invasion. Ferroptosis was evaluated by measuring iron levels, lipid peroxidation, glutathione (GSH) to oxidized glutathione (GSSG) ratio, malondialdehyde (MDA), reactive oxygen species (ROS), and mitochondrial ultrastructure via transmission electron microscopy. Mechanistic studies included molecular docking, Western blot, quantitative polymerase chain reaction (qPCR), apoptosis assays, and pharmacological rescue experiments with ferroptosis inhibitors. A zebrafish xenograft model was used to assess tumor growth in vivo.
Key Findings: Ferroptosis Induction
Nitazoxanide inhibited TNBC cell proliferation, migration, and invasion in both cell lines. It also reduced tumor growth in the zebrafish xenograft model at doses comparable to human clinical use. Critically, NTZ induced ferroptosis rather than apoptosis, as confirmed by the reversal of cell death using ferroptosis inhibitors. The drug caused iron overload, elevated lipid peroxidation markers (MDA and ROS), decreased GSH levels, and damaged mitochondrial structure — all hallmarks of ferroptosis.
Mechanistic Insights
The study identified two parallel mechanisms by which NTZ triggers ferroptosis. First, it disrupted iron homeostasis by upregulating transferrin receptor 1 (TFR1), which increases iron uptake, and downregulating ferroportin 1 (FPN1), which blocks iron export. This dual effect caused iron overload in cancer cells. Second, NTZ promoted β-catenin degradation, which transcriptionally suppressed GPX4 — a key antioxidant enzyme that protects cells from lipid peroxidation. Both β-catenin stabilization and ferroptosis inhibition reversed these effects, confirming the mechanistic pathway. Pharmacological rescue experiments showed that restoring either β-catenin or GPX4 activity partially rescued cells from NTZ-induced death.
Clinical Implications and Limitations
The findings suggest that nitazoxanide could be a readily translatable strategy for TNBC therapy because it is already FDA-approved for human use, has established pharmacokinetics, and showed efficacy at clinically relevant concentrations in preclinical models. However, the study is limited to in vitro and zebrafish xenograft data. No human clinical trials have been conducted. The molecular docking prediction of GPX4 interaction was not experimentally validated. Translating these findings to patients will require phase I/II clinical trials to establish safety, optimal dosing, and efficacy in humans.
You can map out a weight-based schedule using our dosage calculator.
Frequently Asked Questions
What is nitazoxanide?
Nitazoxanide (NTZ) is an FDA-approved antiparasitic drug used to treat parasitic infections caused by protozoa and helminths. It is also known to have broad-spectrum antiviral and antibacterial properties.
What is ferroptosis?
Ferroptosis is a form of programmed cell death caused by iron-dependent lipid peroxidation (damage to cell membranes by reactive oxygen species). It differs from apoptosis (a more common type of programmed cell death) and has emerged as a promising target for cancer therapy.
What is triple-negative breast cancer (TNBC)?
Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks three common receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This makes it resistant to standard hormone and HER2-targeted therapies, leaving chemotherapy as the primary treatment option.
Does this study mean nitazoxanide can treat breast cancer?
No. This study provides preclinical evidence from cell cultures and zebrafish models only. It does not prove that nitazoxanide is effective or safe for treating breast cancer in humans. Clinical trials are needed to evaluate safety, proper dosing, and efficacy before any conclusions about clinical use can be drawn.
What is the evidence level of this study?
This is preclinical evidence (level 5 on the evidence hierarchy). It includes in vitro (cell culture) experiments and a zebrafish xenograft model. No human clinical trials have been conducted.
Nitazoxanide is a drug already approved by the FDA for treating parasitic infections. In a laboratory study using triple-negative breast cancer cells and zebrafish, scientists found that this drug causes a specific type of cell death called ferroptosis — where cells die because of excess iron and oxidative damage. It does this by making cancer cells absorb more iron while blocking iron export, and by destroying a protective protein called GPX4 (glutathione peroxidase 4) that normally shields cells from oxidative damage. This is promising early research, but it has only been tested in cells and zebrafish, not in humans.
Shop Sanare Lab
Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.
Veterinary-grade benzimidazole compound studied in preclinical cancer research.
Broad-spectrum antiparasitic with emerging preclinical evidence in oncology.
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
References
- Zhang C, Yang T, Meng Y. Repurposing nitazoxanide as a novel ferroptosis inducer for triple-negative breast cancer via dual disruption of iron homeostasis and the β-catenin/GPX4 axis. Redox Rep. 2026;31(1):2695689. doi:10.1080/13510002.2026.2695689
Medical Disclaimer
This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. The content discusses preclinical research findings and should not be interpreted as a recommendation for any specific therapy. Always consult a licensed healthcare professional before making any medical decisions.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.